Forecast Period | 2025-2029 |
Market Size (2023) | USD 4.93 Billion |
CAGR (2024-2029) | 4.58% |
Fastest Growing Segment | Laboratory Instruments |
Largest Market | North America |
Market Size (2029) | USD 6.38 Billion |
Market Overview
Global Clinical Microbiology Market was valued at USD
4.93 Billion in 2023 and is expected to reach USD 6.38 Billion by 2029 with a
CAGR of 4.58% during the forecast period. This growth reflects the critical
role of clinical microbiology in healthcare and the continuous evolution of
technologies that enhance diagnostic accuracy and efficiency.
Technological innovations are a key driver of the
clinical microbiology market. The development and integration of advanced
diagnostic techniques, such as molecular diagnostics, next-generation
sequencing (NGS), and automation, have significantly improved the speed and
accuracy of microbial identification and characterization. Molecular diagnostic
tools, including polymerase chain reaction (PCR) and loop-mediated isothermal
amplification (LAMP), enable rapid and precise detection of pathogens, reducing
the time required for diagnosis and treatment.
Next-generation sequencing has revolutionized the
field by allowing for comprehensive analysis of microbial genomes, providing
insights into the genetic makeup of pathogens and their resistance mechanisms.
Automation in microbiology laboratories has also enhanced workflow efficiency,
reducing manual intervention and increasing throughput. These advancements are
pivotal in managing and controlling infectious diseases, driving market growth.
The increasing prevalence of infectious diseases,
including emerging and re-emerging pathogens, is a significant factor
contributing to the growth of the clinical microbiology market. The COVID-19
pandemic underscored the importance of rapid and accurate diagnostic methods in
managing global health crises. The market continues to benefit from the
heightened awareness and investments in diagnostics for infectious diseases,
including bacterial, viral, fungal, and parasitic infections.
The rise in antibiotic-resistant infections, driven
by the misuse and overuse of antibiotics, further emphasizes the need for
advanced microbiological testing. Clinical microbiology plays a crucial role in
identifying resistant strains and guiding appropriate treatment strategies,
which is essential for combating the global challenge of antimicrobial
resistance.
There is a growing demand for point-of-care (POC)
diagnostics, which offer rapid and convenient testing at or near the patient’s
location. POC testing devices and systems in clinical microbiology enable
timely diagnosis and treatment, particularly in remote or underserved areas.
The convenience and speed of POC diagnostics contribute to improved patient
outcomes and reduced healthcare costs, driving their adoption across various
healthcare settings.
Regulatory approvals and reimbursement policies
significantly impact the clinical microbiology market. Regulatory agencies,
such as the U.S. Food and Drug Administration (FDA) and the European Medicines
Agency (EMA), play a crucial role in ensuring the safety and efficacy of
diagnostic products. Streamlined regulatory processes and favorable
reimbursement policies for innovative diagnostic solutions facilitate market
entry and expansion.
Government and healthcare organizations are
increasingly recognizing the value of investing in advanced diagnostic
technologies. Supportive policies and funding for research and development
further enhance the growth prospects of the clinical microbiology market.
The future of the clinical microbiology market
looks promising, with continued advancements in technology, increasing demand
for rapid diagnostics, and growing investments in healthcare infrastructure. As
the global population grows and healthcare needs evolve, the demand for
accurate, efficient, and accessible microbiological testing will continue to
drive market growth.
Key Market Drivers
Rising Incidence of Infectious Diseases
The global clinical microbiology market is
experiencing significant growth, largely driven by the rising incidence of
infectious diseases. This trend highlights the critical role of clinical
microbiology in diagnosing, managing, and controlling a wide array of
infectious agents. The increasing prevalence of infections, coupled with the
need for precise and rapid diagnostic methods, underscores the importance of
clinical microbiology in contemporary healthcare.
The global rise in infectious diseases, including
both emerging and re-emerging pathogens, is a primary factor driving the demand
for clinical microbiology services. Diseases such as influenza, tuberculosis,
HIV/AIDS, and more recently, COVID-19, have placed immense pressure on
healthcare systems worldwide. The frequent outbreaks of new and persistent
infections necessitate robust microbiological testing to ensure effective
diagnosis and treatment.
According to Statista's 2024 report, there were 247
million reported cases of malaria in 2022. This was followed by 10.6 million
cases of tuberculosis, 369,581 cases of mumps, 223,370 cases of cholera,
205,153 cases of measles, 174,059 cases of leprosy, 62,646 cases of pertussis,
17,836 cases of rubella, 6,651 cases of tetanus, and 5,856 cases of diphtheria,
among others.
The emergence of antibiotic-resistant bacteria has
further exacerbated the issue, creating a critical need for accurate
susceptibility testing and antimicrobial stewardship. The growing burden of
infectious diseases has highlighted the importance of early detection and
precise identification of pathogens, driving the demand for advanced clinical
microbiology technologies.
The rising incidence of infectious diseases has
spurred significant advancements in diagnostic technologies within the clinical
microbiology sector. Innovations such as polymerase chain reaction (PCR),
next-generation sequencing (NGS), and rapid antigen tests have revolutionized
pathogen detection and identification. These technologies enable faster and
more accurate results, which are crucial for timely patient management and
outbreak control.
Automated systems and high-throughput diagnostic
platforms have also enhanced the efficiency of microbiological testing. The
integration of these advanced technologies with clinical workflows facilitates
the rapid processing of large volumes of samples, addressing the increasing
demand for timely diagnostics in high-burden settings.
The rising incidence of infectious diseases
emphasizes the need for global health security and preparedness. Governments
and health organizations are increasingly investing in surveillance systems,
diagnostic infrastructure, and research initiatives to combat infectious
threats. The focus on strengthening global health security drives investments
in clinical microbiology, as robust diagnostic capabilities are essential for
detecting and managing infectious diseases on a global scale.
Public health initiatives and response strategies
are reliant on accurate and reliable microbiological testing. This dependence
underscores the crucial role of clinical microbiology in monitoring disease
outbreaks, tracking pathogen trends, and implementing effective public health
interventions.
Preventive healthcare measures and routine screening
programs are becoming more prevalent in response to the rising incidence of
infectious diseases. Regular screenings for sexually transmitted infections
(STIs), respiratory infections, and other communicable diseases drive the
demand for clinical microbiology services. These preventive measures aim to
identify infections early and prevent their spread, highlighting the importance
of ongoing diagnostic testing.
The expansion of vaccination programs and health
education campaigns also contributes to the increased need for microbiological
testing. Monitoring vaccine efficacy and conducting post-vaccination
surveillance are essential for ensuring public health and preventing disease
outbreaks.
The escalating incidence of infectious diseases
fosters research and innovation in the clinical microbiology field. Scientists
and researchers are continuously developing new diagnostic tools, exploring
novel biomarkers, and studying pathogen resistance mechanisms. This research
drives the evolution of microbiological testing methods and supports the growth
of the market by addressing emerging diagnostic needs.
Collaboration between academic institutions,
research organizations, and industry players accelerates the development of
advanced diagnostic technologies. The focus on research and innovation ensures
that clinical microbiology remains at the forefront of combating infectious
diseases and meeting evolving healthcare challenges.
Advancements in Diagnostic Technologies
The global clinical microbiology market is witnessing
transformative growth, largely driven by rapid advancements in diagnostic
technologies. These technological innovations are reshaping the landscape of
microbial diagnostics, offering unprecedented capabilities for the detection,
identification, and management of infectious diseases.
One of the primary drivers of market growth is the
significant improvement in the accuracy and speed of diagnostic tests.
Traditional microbiology methods, such as culture-based techniques, often
require several days to provide results. In contrast, modern diagnostic
technologies, including polymerase chain reaction (PCR), next-generation
sequencing (NGS), and real-time PCR, offer much faster turnaround times. These
technologies enable clinicians to obtain results within hours, facilitating
quicker decision-making and timely treatment interventions.
Advanced molecular diagnostics, such as PCR and
NGS, enhance the accuracy of microbial identification by detecting specific
genetic material from pathogens. This precision reduces the likelihood of false
positives and negatives, ensuring that patients receive accurate diagnoses and
appropriate treatments. The increased speed and accuracy of these technologies
are crucial for managing infectious diseases, particularly in emergency and
critical care settings.
Automation and artificial intelligence (AI) are
revolutionizing diagnostic processes, making them more efficient and reducing
the potential for human error. Automated systems streamline laboratory
workflows, from sample preparation to data analysis, thereby increasing
throughput and consistency. For example, automated liquid handling systems and
robotic analyzers facilitate high-throughput testing, enabling laboratories to
process large volumes of samples with minimal manual intervention.
AI and machine learning algorithms are being
integrated into diagnostic platforms to enhance data analysis and
interpretation. These technologies can analyze complex data sets, identify
patterns, and provide predictive insights that aid in diagnosing and monitoring
infectious diseases. By leveraging AI, clinical microbiology laboratories can
improve diagnostic accuracy, optimize resource utilization, and accelerate the
development of personalized treatment plans.
Multiplexing technologies represent another
significant advancement, allowing for the simultaneous detection of multiple
pathogens from a single sample. This capability is particularly valuable in
clinical microbiology, where patients may present with symptoms that could be
caused by a range of microorganisms. Multiplex PCR and multiplex immunoassays
enable comprehensive testing for various pathogens, reducing the need for
multiple tests and improving diagnostic efficiency.
These technologies are instrumental in managing
outbreaks and monitoring public health. For instance, during an infectious
disease outbreak, multiplex assays can rapidly identify multiple pathogens,
facilitating a swift public health response and informing appropriate
containment strategies.
The rise of point-of-care (POC) testing is further
driving the growth of the clinical microbiology market. POC diagnostics are
designed to provide rapid results at or near the patient’s location, such as in
clinics, emergency rooms, or even at home. These tests are particularly valuable
in settings where timely diagnosis is critical, such as in remote or
underserved areas.
Advancements in POC technologies, including
portable PCR devices and handheld immunoassay systems, are expanding access to
diagnostic testing and improving patient outcomes. By enabling on-the-spot
testing, POC diagnostics reduce the time required to initiate treatment and
minimize the need for follow-up visits, thus enhancing overall healthcare
efficiency.
The regulatory landscape is also evolving to
support the adoption of advanced diagnostic technologies. Regulatory agencies
are streamlining approval processes for new diagnostic devices and assays,
facilitating faster market entry. As regulatory pathways become more efficient,
innovative technologies can reach healthcare providers and patients more
quickly, driving market growth.
Download Free Sample Report
Key Market Challenges
Evolving Microbial Threats
The global clinical microbiology market faces
significant challenges, with evolving microbial threats emerging as a critical
concern. As pathogens continue to evolve and adapt, the complexities of
diagnosing and managing infectious diseases intensify.
Evolving microbial threats are characterized by the
emergence of new pathogens and the adaptation of existing ones, leading to
increased difficulty in detection, treatment, and prevention. The rise of
antimicrobial-resistant (AMR) organisms, novel viral strains, and re-emerging
infectious diseases poses substantial challenges to global health systems and
clinical microbiology.
Antimicrobial resistance is one of the most
pressing challenges. The proliferation of resistant strains of bacteria,
viruses, fungi, and parasites threatens to render existing treatments
ineffective. Resistant pathogens, such as multi-drug-resistant (MDR)
tuberculosis and methicillin-resistant Staphylococcus aureus (MRSA), complicate
treatment regimens and increase healthcare costs. The clinical microbiology
market must adapt to these challenges by developing advanced diagnostic tools
to identify resistant strains and guide appropriate treatment strategies.
The emergence of novel pathogens, including newly
discovered viruses and bacteria, adds to the complexity of disease management.
For instance, the COVID-19 pandemic underscored the rapid evolution of viruses
and the need for robust diagnostic and monitoring systems. Similarly, the
emergence of zoonotic diseases and pathogens with pandemic potential requires
continuous surveillance and innovation in diagnostic methodologies.
Re-emerging infectious diseases, such as Ebola and
Zika viruses, pose significant threats due to their potential to cause
widespread outbreaks. These diseases often present unique challenges in terms
of rapid detection and containment. The clinical microbiology market must
enhance its capabilities to address these re-emerging threats, including the
development of rapid diagnostic assays and effective response strategies.
Key Market Trends
Increased Focus on Rapid Diagnostics
The global clinical microbiology market is
undergoing a significant transformation, driven by an increased focus on rapid
diagnostics. This trend is reshaping the landscape of disease detection and
management, influencing both the technology and practices within the field. As
the demand for timely and accurate diagnostic solutions grows, rapid
diagnostics are becoming central to clinical microbiology, offering substantial
benefits across various healthcare settings.
In recent years, there has been a marked shift
towards rapid diagnostic solutions in clinical microbiology. Traditional
diagnostic methods often involve lengthy procedures and extended waiting times
for results, which can delay treatment and affect patient outcomes. In
contrast, rapid diagnostic tests (RDTs) provide quicker results, enabling
healthcare professionals to make informed decisions more swiftly. This shift is
particularly crucial in the management of infectious diseases, where timely
intervention is essential to prevent outbreaks and reduce morbidity and
mortality rates.
In 2023, researchers at Queensland University of
Technology (QUT) introduced an innovative method for designing molecular ON-OFF
switches utilizing proteins. This new approach has broad potential applications
in biotechnology, biomedicine, and bioengineering. The QUT research team has
demonstrated that this advanced technique enables the development of faster and
more precise diagnostic tests for disease detection, water quality monitoring,
and environmental pollutant identification.
The advancement of diagnostic technologies is a
major driver behind the increased focus on rapid diagnostics. Innovations such
as molecular diagnostics, including polymerase chain reaction (PCR) and
next-generation sequencing (NGS), have revolutionized the field by enabling the
rapid detection of pathogens at the genetic level. These technologies offer
high sensitivity and specificity, significantly reducing the time required to
obtain accurate results. Additionally, advancements in point-of-care testing
(POCT) devices have made it possible to conduct diagnostics at the bedside or
in remote locations, further enhancing the speed of diagnosis.
The integration of rapid diagnostics into clinical
microbiology has profound implications for patient management. Faster
diagnostic results lead to quicker initiation of appropriate treatments,
improving patient outcomes and reducing the risk of complications. For
instance, in the case of bacterial infections, early identification of the
causative pathogen allows for targeted antibiotic therapy, which can mitigate
the development of antibiotic resistance and improve recovery rates.
Furthermore, rapid diagnostics are instrumental in managing infectious disease
outbreaks, allowing for prompt public health responses and containment
measures.
The emphasis on rapid diagnostics is also driven by
economic considerations. Reducing the turnaround time for diagnostic results
translates into cost savings for healthcare systems by minimizing the need for
prolonged hospital stays and repetitive testing. This economic efficiency is a
key factor in the growing adoption of rapid diagnostic technologies. As
healthcare providers and institutions seek to enhance operational efficiency
and patient care, the demand for rapid diagnostics continues to rise,
contributing to the overall growth of the clinical microbiology market.
Despite the benefits, there are challenges
associated with the widespread implementation of rapid diagnostics. These
include the high cost of advanced technologies, the need for specialized
training, and the integration of new systems into existing workflows. However,
ongoing research and development efforts aim to address these challenges by
focusing on cost reduction, user-friendly designs, and seamless integration
into clinical practices.
Looking ahead, the trend towards rapid diagnostics
is expected to intensify as new technologies emerge and healthcare demands
evolve. The continuous innovation in diagnostic tools and the growing emphasis
on early detection and treatment will likely drive further advancements in the
field of clinical microbiology.
Segmental Insights
Product Insights
Based on Product, Laboratory Instruments have
emerged as the fastest growing segment in the Global Clinical Microbiology Market
in 2023. Technological innovations are a major driver of growth in laboratory
instruments used in clinical microbiology. Modern laboratory instruments, such as
automated analyzers, molecular diagnostic tools, and advanced culture systems,
have revolutionized the diagnostic process. For instance, the introduction of
next-generation sequencing (NGS) technologies and real-time polymerase chain
reaction (PCR) has enabled rapid and precise detection of pathogens. These
advancements enhance diagnostic accuracy, speed up results, and provide
valuable insights into microbial genomics, which are essential for effective
disease management.
The rising prevalence of infectious diseases,
including emerging and re-emerging pathogens, has amplified the need for
advanced laboratory instruments. The COVID-19 pandemic highlighted the critical
role of efficient diagnostic tools in managing public health crises. The demand
for accurate and timely detection of a broad spectrum of pathogens—ranging from
bacteria and viruses to fungi and parasites—drives the adoption of
sophisticated laboratory instruments. This trend is evident in the growing
market for automated systems that can handle high-throughput testing and
provide reliable results in a shorter timeframe.
Antimicrobial resistance (AMR) is a significant
global health challenge, prompting the need for advanced diagnostic
capabilities to identify resistant strains of pathogens. Laboratory instruments
that offer detailed susceptibility testing and resistance profiling are crucial
in combating AMR. Automated susceptibility testing systems and molecular
diagnostics that detect resistance genes are increasingly in demand, as they
provide critical information for effective treatment and infection control. The
growth of AMR awareness and research contributes to the expansion of the market
for specialized laboratory instruments.
The growing demand for point-of-care (POC)
diagnostics and rapid testing solutions is driving the development and adoption
of innovative laboratory instruments. POC testing devices, which allow for
on-site and immediate diagnostic results, are particularly valuable in
emergency settings, remote locations, and resource-limited environments.
Laboratory instruments designed for POC applications, such as portable
analyzers and compact testing kits, are gaining traction due to their
convenience and efficiency. The shift towards rapid diagnostics aligns with the
need for timely intervention and improved patient outcomes.
The integration of automation and digitalization in
laboratory processes is transforming the clinical microbiology landscape.
Automated systems streamline workflows, reduce manual errors, and increase
throughput, making them essential for high-volume laboratories. Additionally,
digital solutions, such as laboratory information management systems (LIMS) and
data analytics platforms, facilitate data management and integration, enhancing
overall efficiency. The push towards automation and digitalization drives the
demand for advanced laboratory instruments that can seamlessly integrate with
these technologies.
Increased research and development (R&D)
activities in clinical microbiology are fueling the demand for cutting-edge
laboratory instruments. Researchers and scientists require sophisticated tools
to explore microbial behavior, study pathogenic mechanisms, and develop new
diagnostic methods and treatments. Investments in R&D by both public and
private sectors drive innovation in laboratory instrumentation, supporting the
advancement of clinical microbiology and expanding the market for
high-performance analytical equipment.
Regulatory standards and quality assurance
requirements play a crucial role in shaping the laboratory instruments market.
Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and
the European Medicines Agency (EMA), enforce stringent guidelines for
diagnostic equipment to ensure accuracy, reliability, and safety. Compliance
with these regulations drives the development and adoption of high-quality
laboratory instruments, further contributing to market growth.
Disease Insights
Based on Disease, Respiratory Diseases have emerged
as the dominating segment in the Global Clinical Microbiology Market during the
forecast period. Respiratory diseases, including influenza, pneumonia,
tuberculosis, chronic obstructive pulmonary disease (COPD), and more recently,
COVID-19, represent a substantial portion of the global disease burden. These
conditions are among the leading causes of morbidity and mortality worldwide,
particularly affecting vulnerable populations such as the elderly, children,
and individuals with pre-existing health conditions.
The high prevalence of respiratory infections and
their significant impact on public health drive substantial demand for
diagnostic services. Accurate and timely detection of pathogens responsible for
respiratory diseases is essential for effective treatment and management,
fueling the growth of the clinical microbiology market.
The evolution of diagnostic technologies has
significantly enhanced the ability to detect and identify respiratory
pathogens. Innovations such as polymerase chain reaction (PCR), rapid antigen
tests, and next-generation sequencing (NGS) have revolutionized the field of
clinical microbiology. These advanced methods enable rapid, sensitive, and
specific detection of respiratory pathogens, facilitating early diagnosis and
improving patient outcomes.
Automated diagnostic platforms and high-throughput
testing systems have further advanced the ability to manage large volumes of
respiratory samples efficiently. The integration of these technologies into
clinical practice supports the growing demand for precise and reliable
microbiological testing in the context of respiratory diseases.
The COVID-19 pandemic has significantly amplified
the focus on respiratory diseases within the clinical microbiology market. The
global outbreak of SARS-CoV-2 highlighted the critical need for rapid and
accurate diagnostic testing to control the spread of the virus, diagnose cases,
and monitor patient recovery. The pandemic led to unprecedented investments in
diagnostic technologies and research, driving advancements in respiratory
disease diagnostics and expanding the market.
The increased emphasis on COVID-19 testing has also
elevated awareness and resources dedicated to other respiratory infections. The
pandemic's impact on healthcare systems worldwide has underscored the
importance of robust diagnostic infrastructure and preparedness for respiratory
disease outbreaks.
Seasonal respiratory infections, such as influenza
and respiratory syncytial virus (RSV), contribute to the ongoing demand for
diagnostic testing. Seasonal outbreaks require timely and accurate diagnostics
to implement effective public health measures and manage patient care.
Chronic respiratory conditions, including COPD and
asthma, also drive demand for clinical microbiology services. These conditions
often involve complex microbial interactions and co-infections that require
comprehensive diagnostic approaches for effective management and treatment.
Preventive healthcare measures, including
vaccination programs for respiratory diseases such as influenza and COVID-19,
drive the need for ongoing diagnostic testing. Monitoring vaccine efficacy,
conducting post-vaccination surveillance, and detecting vaccine-related adverse
effects are essential components of preventive healthcare that support the
clinical microbiology market.
The emphasis on preventive measures and early
detection of respiratory infections underscores the need for accurate and
reliable diagnostic tools to support public health initiatives and improve patient
outcomes.
Research and development in the field of
respiratory diseases continue to drive innovation in clinical microbiology.
Advances in understanding the pathogenesis of respiratory infections, the
identification of new biomarkers, and the development of novel diagnostic
assays contribute to market growth.
Collaboration between research institutions,
healthcare providers, and industry stakeholders fosters the development of
cutting-edge diagnostic technologies and supports the expansion of the clinical
microbiology market.
Download Free Sample Report
Regional Insights
Based on Region, North America have emerged as the
dominating region in the Global Clinical Microbiology Market in 2023. One of
the primary reasons for North America's dominance in the clinical microbiology
market is its advanced healthcare infrastructure. The region boasts some of the
world's leading healthcare facilities and laboratories, equipped with
cutting-edge diagnostic technologies. Major healthcare institutions in the
United States and Canada are at the forefront of employing state-of-the-art
microbiology equipment, including high-resolution mass spectrometry, advanced
molecular diagnostics, and automated systems.
This well-established infrastructure supports high
standards of diagnostic precision and efficiency, contributing to the region’s
leadership in clinical microbiology. The ability to integrate advanced
technologies into routine clinical practice ensures that North America remains
a hub for innovation and excellence in microbial diagnostics.
North America’s dominance is further bolstered by
its robust investment in research and development. The region is home to
numerous world-class research institutions and universities that are driving
advancements in clinical microbiology. These institutions are engaged in
pioneering research that contributes to the development of novel diagnostic
technologies and methodologies.
In the United States, federal agencies such as the
National Institutes of Health (NIH) and the Centers for Disease Control and
Prevention (CDC) play a significant role in funding and supporting research in
microbiology. This investment in R&D fosters innovation and accelerates the
development of new diagnostic tools and techniques, reinforcing North America’s
leading position in the market.
The regulatory environment in North America also
plays a crucial role in the region’s market dominance. Regulatory bodies such
as the U.S. Food and Drug Administration (FDA) and Health Canada maintain
stringent standards for diagnostic products, ensuring that only the most
accurate and reliable technologies are approved for use.
While the regulatory processes are rigorous, they
provide a framework that promotes innovation and ensures high-quality
diagnostic solutions. The clear regulatory pathways and strong support for new
technologies create a favorable environment for the development and
commercialization of advanced diagnostic tools, contributing to North America’s
market leadership.
Significant investments in the clinical
microbiology market by both public and private sectors are a major driver of
North America’s dominance. The region has a high level of investment in
healthcare technology, including funding for new product development,
infrastructure improvements, and market expansion.
Leading diagnostic companies in North America are
continually investing in the development of advanced technologies, such as
molecular diagnostics, automated systems, and point-of-care tests. These
investments not only drive technological advancement but also enhance the
region’s competitive edge in the global market.
North America’s high healthcare expenditure also
contributes to its dominance in the clinical microbiology market. The region’s
substantial investment in healthcare infrastructure and technology reflects a
commitment to improving diagnostic capabilities and patient outcomes. This high
level of expenditure supports the adoption of the latest diagnostic
technologies and the establishment of specialized laboratories, driving market
growth.
Additionally, the growing prevalence of infectious
diseases and the increasing demand for accurate and timely diagnostics drive
market expansion. North America’s proactive approach to managing public health
challenges and investing in advanced diagnostic solutions positions the region
as a leader in clinical microbiology.
Recent Development
- In March 2024, Elsevier, a leading global provider
of scientific, technical, and medical information products and solutions,
announced the launch of a new open-access journal, CMI Communications, in
collaboration with ESCMID, Europe’s premier society in clinical microbiology
and infectious diseases. This new journal will complement ESCMID’s esteemed
official publication, Clinical Microbiology and Infection, by focusing on
translational and clinical aspects of microbiology, infectious diseases,
control measures, immunology, epidemiology, and public health. Authors accepted
for publication in CMI Communications during 2024 and 2025 will benefit from a
50% discount on publication fees.
- In April 2024, Access Microbiology introduced a new
collection on its platform, showcasing studies with negative results published
since its inception in 2019. Negative results are a crucial component of robust
and transparent science, contributing valuable insights to the scientific
literature that is frequently overlooked. The dissemination of negative
findings is essential to prevent redundancy and assist researchers conducting
similar studies. Additionally, sharing these results promotes transparency and
enhances reproducibility in scientific research.
- In April 2024, Bruker introduced significant
upgrades to its clinical microbiology and infection diagnostics portfolio.
These enhancements include a new automated system for preparing MALDI Biotyper
targets and a panel designed for the simultaneous detection of M. tuberculosis
complex bacteria. Bruker also unveiled improvements to its diagnostic solutions
in microbial identification, antimicrobial susceptibility testing (AST), early
sepsis diagnostics, and other infectious disease assays. The latest MALDI
Biotyper, equipped with MBT Compass HT IVD software, boosts throughput to up to
600 samples per hour and features automated instrument tuning via IDealTune.
Additionally, a new optional workflow with the MBT Pathfinder IVD robot offers
semi-automated sample preparation, reducing the need for time-consuming,
repetitive, and error-prone manual tasks.
Key Market Players
- bioMérieux SA
- Becton,
Dickinson and Company
- Danaher
Corporation
- Abbott
Laboratories Inc.
- Hologic,
Inc.
- F.
Hoffmann-La Roche Ltd
- Bruker
Corporation
- Bio-Rad
Laboratories, Inc.
|
By Product
|
By Disease
|
By Region
|
- Laboratory
Instruments
- Automated
Culture System
- Reagents
- Others
|
- Respiratory
Diseases
- Bloodstream
Infection
- Gastrointestinal
Diseases
- Sexually
Transmitted Diseases (STDs)
- Urinary
Tract Infections
- Periodontal
Diseases
- Others
|
- North
America
- Europe
- Asia Pacific
- South
America
- Middle East
& Africa
|
Report Scope:
In this report, the Global Clinical Microbiology
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Clinical Microbiology Market, By Product:
o Laboratory Instruments
o Automated Culture System
o Reagents
o Others
- Clinical Microbiology Market, By Disease:
o Respiratory Diseases
o Bloodstream Infection
o Gastrointestinal Diseases
o Sexually Transmitted Diseases (STDs)
o Urinary Tract Infections
o Periodontal Diseases
o Others
- Clinical Microbiology Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Clinical
Microbiology Market.
Available Customizations:
Global Clinical Microbiology Market report with the
given market data, Tech Sci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Clinical
Microbiology Market is an upcoming report to be released soon. If you wish an
early delivery of this report or want to confirm the date of release, please
contact us at [email protected]